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Retinopathy of prematurity (ROP) is the main cause of avoidable blindness in children inMexico despite National ROP Guidelines
and examination of preterm infants being a legal requirement.Objective. To assess coverage of ROP programs and their compliance
with national guidelines. Study Design. Thirty-two neonatal intensive care units (NICUs) in five of the largest states were visited.
Staff were interviewed to collect information on their ROP programs which were defined as (1) compliant, if National Guidelines
for screening and treatment were followed, (2) noncompliant, if other approaches were used, or (3) no program. Results. Only
10 (31.2%) had fully compliant programs and 11 (34.4%) had no program. In the remaining 11 (34.4%) different screening criteria
were used (7 units): screening was undertaken by an ophthalmologist in unsalaried time (4), was not undertaken in the NICU (2),
and was undertaken by a neonatologist (1) and/or Avastin was used as first-line treatment (7). Poorer states had poorer programs.
Conclusions. Despite legislation mandating eye examination of preterm births, many ROP programs in the largest cities in Mexico
require improvement or need to be established. Prevention of blindness due to ROP needs to be prioritized in Mexico to control
the epidemic of ROP blindness.
1. Introduction
Recent estimates, which used statistical modelling of data
on preterm birth rates, access to neonatal care and survival
rates, rates of retinopathy of prematurity (ROP) requiring
treatment, the proportion of these infants treated, and the
outcome of treatment, suggest that 32,000 preterm infants
(uncertainty range 24,800–44,500) became blind or visually
impaired globally in the year 2010 from ROP [1]. These
estimates are higher than those of a decade ago, which were
based on childhood blindness prevalence estimates and the
proportion of blindness due to ROP [2]. The more recent
estimate suggests that Asia has the highest incidence of blind-
ness due to ROP, followed by Latin America where 3,500
(uncertainty range 2,600–5,200) infants a year are affected
[1]. Analysing the data permillion live births shows that Latin
American countries have a 2.4 times higher incidence of ROP
blindness/severe visual impairment than highly industrial-
ized countries. The study also suggests that approximately
50% of infants developing sight threatening ROP globally
were not treated in 2010.
Retinopathy of prematurity is the commonest cause of
blindness in children in many middle income countries [3],
including Mexico. A recent study in Guadalajara, the capital
of Jalisco State, Mexico, in which 153 blind or severely
visually impaired children in two schools for the blind were
examined, showed ROP to be the commonest cause of blind-
ness (34.7%) [4].The proportion of children less than 10 years
of age who were blind from ROP was higher than those aged
10–15 years (42.3% versus 18.8%), which suggests that ROP is
becoming a more important cause over time. Almost half of
these children (46%) had not been treated for ROP.
The control of visual impairment fromROP requires high
quality neonatal care from the first few minutes after birth,
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coupled with programs for the detection and treatment of
infants who develop the constellation of clinical signs which
indicate a high rate of progression to blinding ROP [5, 6].
Program guidelines need to take account of the population
of infants at risk, which vary by location [3]. Many middle
income countries have national guidelines (e.g., Brazil [7],
Argentina [8], Chile [9], Ecuador, India [10], El Salvador [11],
China [12], Peru [13], andRussia) and have prioritized control
inNational Prevention of Blindness plans. In recognition that
blindness from ROP is a major avoidable cause of blindness
in children in Latin America, the Pan American Health
Organization (PAHO) has prioritized ROP for control in the
region [14–17].Mexico hasNational ROPGuidelines [18], and
legislation has been passed making examination of preterm
infants mandatory [19].TheMexican Guidelines recommend
that infants with birth weights (BW) ≤1,750 g or gestational
age (GA) ≤34 weeks are screened, that is, taking account of
the risk in bigger, more mature infants in middle income
settings. The guidelines were updated in 2010 but did not
include indications for and possible adverse events associated
with intravitreal injection of anti-VEGF agents [18], nor is it
recommended as a primary treatment.
The study in Guadalajara outlined above also investigated
the presence and type of ROP programs in the 17 neonatal
intensive care units (NICUs) in the city, five being in the
private sector [4].NineNICUs, including all five in the private
sector, had ROP programs which complied with national
guidelines. The remaining eight units had programs which
did not comply in one or more respects; that is, infants were
screened in an eye clinic (3 units); parents took their infant
to another NICU for examination after discharge (3 units), or
the neonatologist screened infants at risk (1 unit). At the time
of the study 390 preterm infants could receive care in these
NICUs but only 60% of the 318 cots outside the private sector
had a compliant ROP program.
Mexico has a population of 112 million, with over 2
million births in 2010, over 51,000 (2.5%) being preterm (≤34
weeks of GA). The majority of the preterm infants were born
in the public sector (87%), and in all states most NICUs
are in the state capitals [20]. Mexico has a complex health
systemwith several different health providers.Themajority of
the population now has access to health insurance schemes,
and in 2007 the Popular Insurance scheme covered costs of
neonatal intensive care and treatment of ROP [21]. Despite
improvement in neonatal care and access to insurance, infants
with Stage 5 continue to present to the ROP Clinic in the
Hospital Civil de Guadalajara, many coming from outside
Jalisco State [22]. The purpose of this study was to extend the
earlier study, to assess the presence and quality of programs
for detecting and treating ROP in neonatal units in five states
in Mexico, and to estimate the proportion of infants at risk
of ROP who were receiving care in units with ROP programs
which complied with Mexican ROP National Guidelines.
2. Methods
The study focussed on NICUs in the public sector and was
undertaken in five of the largest states in Mexico, which were
purposively selected. The states visited were Mexico State,
Puebla, the Federal District where the capital city is located,
Jalisco, and Chiapas (Figure 1). These five states account for
approximately 37% of all births. In each state a list of NICUs
was obtained from the Ministry of Health and these were
ranked according to the number of incubators [23], as a
proxy for the number of preterm infants admitted.Thirty-five
NICUs were selected for the study, with the number selected
in each state reflecting the number of known neonatal units
in 2006. Two declined to participate and one was a short stay
unit. The NICUs were visited between June and August 2011.
In each of the 32 NICUs senior neonatal staff were inter-
viewed after explaining the study and obtaining written
informed consent. If the NICU had a program for ROP the
following information was obtained: criteria for screening
and timing of the first examination; who identified the infants
to be screened and who communicated this information
to parents; how the infants were screened and where; who
performed the screening; whether the infants were treated on
the NICU or elsewhere and the method of treatment; which
equipment was used for examination and treatment and
whether this belonged to the NICU. Information was also
sought on who paid for screening and/or treatment. Each
NICU was allocated a study number to maintain confiden-
tiality.
2.1. Categorization of ROP Programs. Programs were classi-
fied as “compliant” if they adhered to the Mexican National
ROPGuidelines; that is, a trained ophthalmologist visited the
NICU on a regular weekly basis in salaried time to screen
infants who fulfilled the eligibility criteria by indirect oph-
thalmoscopy or if they visited smaller NICUs at the request of
the neonatologist when there was an infant to be examined.
Either compliant programs provided laser treatment in the
NICU or infants were transferred to the eye department. Pro-
grams were classified as “noncompliant” if (a) screening did
not adhere to the eligibility criteria, (b) it was not undertaken
regularly, (c) it was performed by a neonatologist, (d) it was
performed by ophthalmologists on a voluntary basis (as this
depends on individual’s motivation and so is not sustainable),
(e) direct ophthalmoscopy was used, or (f) infants were
transferred to an eye department for examination. Programs
were also classified as noncompliant if primary treatment was
with intravitreal Avastin or if parents had to pay for screening
and/or treatment. Units were classified as having no program
if no screening was undertaken and no infants were treated
for ROP.
Data on the number of live births for 2010 were obtained
from the Ministry of Health for populations not receiving
social security [20]. Numbers of preterm infants at risk were
obtained from the Ministry of Health Dynamic Database
[20]. Data on neonatal service delivery for 2006, the most
recent year, were also obtained from the Ministry of Health
to provide information on the NICU’s location [23]. All data
were collected by one researcher (L. Consuelo Zepeda-
Romero).
The study was approved by the ethics committee of the
London School of Hygiene & Tropical Medicine and by the
Ministry of Maternal and Child Health in Mexico.
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Figure 1: Map of Mexico showing the location of the states included in the study.
Table 1: Type of program for ROP in 32 neonatal units in five states in Mexico, including number and proportion of cots.
Compliant program Noncompliant program No program
𝑁 % of units % of cots 𝑁 % of units % of cots 𝑁 % of units % of cots
General hospital𝑁 = 18 (191 cots) 7 (87) 38.9% 45.5% 4 (50) 22.2% 26.2% 7 (54) 38.9% 28.3%
Maternity hospital𝑁 = 8 (128 cots) 1 (16) 12.5% 12.5% 5 (82) 62.5% 64.1% 2 (30) 25% 23.4%
Children’s hospital𝑁 = 6 (53 cots) 2 (19) 33.3% 35.8% 2 (22) 33.3% 41.5% 2 (12) 33.3% 22.6%
All NICUs𝑁 = 32 (372 cots) 10 (122) 31.2% 32.8% 11 (154) 34.4% 41.4% 11 (96) 34.4% 25.8%
3. Results
3.1. Types and Coverage of ROP Programs. Only 10 units
(31.2%) had a fully compliant program, that is, for screening
and treatment, but 5 transported infants to the eye clinic for
treatment. General hospitals weremore likely to have compli-
ant programs (38.9%) than children’s or maternity hospitals
(33.3% and 12.5%, resp.) (Table 1). A third (34.4%) of study
NICUs did not have a program for ROP and a further 34.4%
of NICUs had noncompliant programs (Table 1). As the
NICUs without ROP programs tended to be smaller, the
proportion of the 372 cots without a program was 25.8%
with 41.4%being inNICUswith noncompliant programs.The
wealthier states (Federal District, Mexico State, and Jalisco)
had a higher proportion of compliant ROP programs, and
Chiapas and Puebla, the poorer states, had the lowest cover-
age (Table 2). In Chiapas only one of the six units had a pro-
gram, which was classified as noncompliant as parents paid
for screening and Avastin treatment. In several other NICUs
in Chiapas parents were informed that their child was at risk
of blindness from ROP and they were advised to take their
child to an ophthalmologist.
3.2. Details of Procedures for Screening. Twenty-one of the 32
(65.5%) NICUs had some mechanism for screening infants
(Table 3). In seven of the general hospitals ophthalmologists
from the eye department screened infants in the NICU in
salaried time. In four hospitals screening was by ophthalmol-
ogists who did this on a voluntary basis, two being maternity
hospitals. In one maternity hospital a neonatologist screened
infants by indirect ophthalmoscopy and in two NICUs the
RetCam imaging system was used to document findings.
Infants transferred to the eye department for screening were
often not stable enough for transfer until they were over 6
weeks of age.Most of the hospitals provided indirect ophthal-
moscopes while the unsalaried ophthalmologists provided
their own equipment. In two units where screening was not
4 BioMed Research International
Table 2: Type of program in neonatal units in five states in Mexico, ranked by wealth status.
States ranked by wealth Compliant program Noncompliant program No program Total
𝑁 % 𝑁 % 𝑁 % 𝑁 %
Federal District 3 33% 1 11% 5 56% 9 100%
Mexico State 3 38% 4 50% 1 13% 8 100%
Jalisco 3 60% 2 40% 0 0% 5 100%
Puebla 1 25% 3 75% 0 0% 4 100%
Chiapas 0 0% 1 17% 5 83% 6 100%
Total 10 31.2% 11 34.4% 11 34.4% 32 100%
performed, visually evoked potentials were used to detect
ROP at discharge.
3.2.1. Screening Criteria. Amongst the 21 NICUswith an ROP
program, 14 (66.6%) followed the Mexican Guidelines but 7
used much narrower criteria; that is, BW ≤1,200 g or GA <32.
Two had adjusted the criteria on the basis of their own data
but the other five followed criteria from other countries.
3.3. Details of Procedures for Treatment. Laser treatment was
the most frequent form of treatment (in all 10 compliant
programs). Five of the general hospitals owned a laser, and
the other ophthalmologists treating with laser either rented
the equipment or the infant was transferred and treated in the
eye department. Avastin was the treatment of choice in seven
units. In six of these units the ophthalmologists were either
unsalaried (3 units) or were private practitioners (3 units)
(Table 3). In some units Avastin was reportedly used because
of lack of anaesthetists.
3.3.1. Who Paid for Screening and Treatment? In four of the
11 units with a noncompliant program, parents paid for
different aspects of care. In three units parents paid private
ophthalmologists for screening and treatment with Avastin.
In another unit parents paid for transport to the eye clinic for
screening and laser treatment, which cost 400US$. In the 17
other units (i.e., all 10 compliant programs and 7 noncom-
pliant programs) the health provider paid for screening and
treatment.
3.3.2. Characteristics of Study Neonatal Intensive Care Units.
Twenty-nine of the 32 NICUs visited were in the Secretaria de
Salud (SSA) health system,with a total of 345 spaces for inten-
sive neonatal care. This represents approximately a third of
the provision of preterm care in Mexico’s SSA health system.
Two were in the state government health system and one was
in the InstituteMexican Social Security (IMSS) health system.
Eighteen of the study NICUs were in general hospitals, 8
were inmaternity hospitals, and 6were in children’s hospitals.
Fifteen of the 24 general or maternity hospitals admitted high
risk pregnancies and 11 were referral centres (Table 4).
3.4. Other Findings. In several of the general hospitals with
eye departments the ophthalmologists reported that infants
with Stage 5 ROP were seen on a regular basis, usually from
outside the state.
4. Discussion
The findings of this study show that much needs to be done
to improve the coverage and quality of programs for the
detection and treatment of ROP inMexico, even in the capital
city where five of the nine NICUs visited did not have a
program.Greater awareness is needed amongst policymakers
and planners, so that they are made aware of PAHO priorities
for the region and the National ROP Guidelines and that
eye examination of preterm infants is a legal requirement. At
the time of the study ROP was not included in the National
Prevention of Blindness plans for Mexico, despite treatment
being covered by national insurance schemes, and this needs
to be addressed as a matter of urgency. Greater awareness is
also needed amongst the professional organizations of paedi-
atricians, neonatologists, and ophthalmologists so that ROP
is included in all residency programs.
Parents need to be better informed about ROP so they
know that eye examination of all preterm infants is not only
necessary but is a legal requirement of providers (since Jan-
uary 2013) so that they demand services [19]. However, moth-
ers of preterm infants inMexico are often very young, unmar-
ried, poorly educated, and unemployed [22]. Any educational
materials will need to be clear and easy to understand by those
with a poor educational background. Better communication
will be needed between ophthalmologists and the neonatal
team so that mothers can be informed of the need for
screening while in the unit and that further examinationmay
be required after discharge.
A shortage of ophthalmologists who are willing to screen
is a major constraint in many settings, which has been
addressed in other countries, such as Brazil [7], Argentina
[8], Chile [9], and China, by policies which allow ophthal-
mologists to screen in salaried time. However, the complexity
of the health system in Mexico makes implementing policies
challenging. Many of the ophthalmologists did not visit the
unit to screen infants on a regular basis (i.e., on the same
day of the week) which makes follow up of discharged
infants impossible. In five units ophthalmologists were not
using the Mexican criteria for screening [18] but were using
the narrower criteria adopted by more advanced economies
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Table 4: Number of neonatal units included in the study by hospital type and the proportion of all cots in each state included in the study.
Study states General hospital Maternity hospital Children’s hospital Total visited % of cots in state in 2010
Federal District 3 3 3 9 42.7%
Mexico State 4 3 1 8 56.2%
Jalisco 4 1 0 5 46.3%
Puebla 2 1 1 4 42.3%
Chiapas 5 0 1 6 38.4%
Total 18 8 6 32 45.2%
where the population of infants at risk is very different. Both
of these factors make it likely that infants who develop ROP
needing treatment are not being screened at all or are not
being examined after discharge.
Different approaches to screening are being explored and
used, including retinal imaging by neonatologists, nurses, or
trained nonphysicians [24], with interpretation of the images
at the cot side or through telemedicine [25]. It is likely that
new, less expensive cameras suitable for screening preterm
infants will soon become available, which offers a paradigm
shift in screening, whereby members of the neonatal team
could be trained to obtain and interpret retinal images at the
cot side, only calling an ophthalmologist to examine infants
detected with ROP where treatment may be needed. This
approach has the potential to greatly increase the coverage of
screening for ROP.
Several units lacked access to a laser, but this problem can
be addressed by sharing a laser, as occurs in some cities in
other countries. InMexico this may be challenging, given the
different health systems and range of providers. Despite laser
treatment being covered by health insurance inMexico,many
providers are not availing themselves of this opportunity as
reimbursement processes can be slow and cumbersome, and
the fee may go to the hospital rather than the individual pro-
viding the treatment. Under these circumstances families are
bearing the costs unnecessarily [21, 26]. Many of the families
of infants cared for in government facilities are poor, and the
out of pocket expenditure for laser treatment is likely to have
adverse consequences, but this was not explored in this study.
Advocacy will be needed so that health providers cover all
costs of the program and to ensure that ophthalmologists are
adequately reimbursed for their time. In several units infants
were transported to eye clinics for treatment, which is not
desirable as it increases stress for the infants, takes staff away
from the neonatal unit, and may lead to delay in treatment.
It is also of concern that almost a quarter of the oph-
thalmologists used Avastin as a first line therapy when so
little is known about the long term ocular and systemic
complications [27], despite the Mexican Guidelines stating
that antiangiogenic agents should only be used when laser
treatment has failed [28]. Lack of anaesthetists was the reason
given by some, but laser treatment can be delivered safely
under topical anaesthesia with sedation in the presence of
a neonatologist [29]. Many of the ophthalmologists using
Avastin were private or “volunteer” ophthalmologists, where
the ease and speed of treatment with Avastin compared with
lasermay be a factor, but this was not explored.There needs to
be greater awareness of the potential complications of Avastin
among neonatologists and ophthalmologists until further
trials indicate that lower doses or different preparations are
not only effective but safe.
A limitation of this study is that it only includedNICUs in
state capital cities. However, as the majority of ophthalmolo-
gists inMexico work in themajor cities, the provision of ROP
programs is likely to be even poorer outside state capitals.The
present study provides a baseline which can be used to assess
change in the coverage and quality of ROP programs over
time in response to change in policies and greater awareness
amongst service providers and parents.
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